To the editor:

Using orally administered deuterium-labeled water to label neutrophils in vivo, Pillay et al measured urinary and blood deuterium-to-proton enrichment ratios at intervals of ∼ 12 days over several weeks before and after termination of intake.1  From mathematical modeling they obtained a median peripheral blood (PB) human neutrophil lifespan of 5.4 days.

This result is highly surprising in view of the range of neutrophil labeling techniques, including whole blood labeling with DFP-322 ; in vivo H-3 labeling followed by blood transfusion3 ; and in vitro labeling of purified neutrophils with Cr-51,4  In-111,5  or Tc-99m,5  which have all previously given a PB lifespan of ∼ 10 hours. It is also starkly at odds with the clinical observations of rapid neutrophil depletion after myeloablative chemotherapy (within 3-5 days) and short-lived normalization of neutrophil counts following therapeutic granulocyte infusion (1-2 days).

We wish to raise several objections to the work of Pillay et al.

  1. Bone marrow is a major site of neutrophil destruction as well as development,6  but there is no discussion on the availability of deuterium-labeled adenosine for salvage that might result in reutilization in newly dividing neutrophil precursors.

  2. The authors claim their previous work on human lymphocytes,7  based on similar sampling intervals, validates their modeling, but lymphocytes had a reported lifespan of > 100 days, long enough to be measurable from the sampling interval used.

  3. The reported peak (63-day) enrichment in blood (4.3× urine value) is unexplained. Urine enrichment is consistent with the deuterium dose (see supplemental Data, available on the Blood Web site; see the Supplemental Materials link at the top of the online letter), but blood enrichment is inexplicably high. The authors introduced an “amplification factor” c between urine and blood enrichment ratios, attributing this to the multiple hydrogen atoms in a single adenosine deoxyribose moiety. However, the deuterium enrichment ratio at a particular hydrogen location in a molecule is unlikely to depend on the number of hydrogen locations in a molecule, so the high blood enrichment remains unexplained.

  4. A possible explanation for the high deuterium enrichment in blood may lie in the fact that reactions involving the cleavage of bonds to hydrogen occur at a faster rate compared with deuterium (∼ 7× faster for C-H compared with C-D),8  which results in a longer residence time for deuterium.9  This is known as the kinetic isotope effect.8  If this effect is important during neutrophil development, it may explain the elevated blood deuterium enrichment, but at the same time would cast doubt over almost any kind of modeling, unless the mechanism and location of deuterium enrichment were well understood.

We present an alternative, simpler model that critically assumes a neutrophil PB lifespan that is negligible relative to the development time of neutrophils in marrow. Thus, instead of using 3 parameters (ie, the scaling factor [a] for the difference between urine and blood deuterium enrichments, the time of neutrophil development in marrow and the PB lifespan), we found that the data in the authors' published figures could be equally well fitted using only 2 parameters (a and a simple delay between urine and blood enrichment curves; see their supplemental data). This model gave small residuals, no evidence of systematic deviation from the data, and a delay of 11.2 days (Figure 1). Interestingly, the fit was improved using a distribution of delays, which, although a more likely scenario, appears not to have been considered by the authors.

Figure 1

Modeling of blood data. Modeling of blood data using blood deuterium-to-proton enrichment curves constructed from the authors' published illustrations and the following equation, assuming a negligible PB neutrophil lifespan: bloodenrichment(t)=a*[urine enrichmentcurve(tb)] where a is a scaling factor for the differing urine and blood deuterium enrichments, b is the time interval (delay) between the 2 time-enrichment curves, and t is time. The urine enrichment curve was constructed from the authors' simple exponential model. Fitting gave a delay of 11.2 days, similar to the sum (11.1 days) of the authors' mean values for marrow transit time and PB lifespan.

Figure 1

Modeling of blood data. Modeling of blood data using blood deuterium-to-proton enrichment curves constructed from the authors' published illustrations and the following equation, assuming a negligible PB neutrophil lifespan: bloodenrichment(t)=a*[urine enrichmentcurve(tb)] where a is a scaling factor for the differing urine and blood deuterium enrichments, b is the time interval (delay) between the 2 time-enrichment curves, and t is time. The urine enrichment curve was constructed from the authors' simple exponential model. Fitting gave a delay of 11.2 days, similar to the sum (11.1 days) of the authors' mean values for marrow transit time and PB lifespan.

Close modal

In conclusion, a PB neutrophil lifespan ∼ 13× longer than the currently accepted value is highly unlikely. The authors' conclusion is based on a mathematical model that attempts to resolve total neutrophil lifespan into bone marrow transit time and PB lifespan. Our alternative, simpler model, which assumes a negligible PB lifespan, fits their data just as well as their own model does. The authors' deuterium technique may be sufficient to measure total neutrophil lifespan, and indeed the authors' mean value of 11.1 days (4.8 days in marrow and 6.3 days in PB) is similar to the value given by our model and in line with published values for neutrophil development time in marrow.10  It does not, however, have the temporal resolution to measure a PB lifespan of 10 hours.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Paul S. Tofts, Brighton and Sussex Medical School, University of Sussex, Sussex, BN1 9PX, United Kingdom; e-mail: p.s.tofts@bsms.ac.uk.

1
Pillay
 
J
den Braber
 
I
Vrisekoop
 
N
et al. 
In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days.
Blood
2010
, vol. 
116
 
4
(pg. 
625
-
627
)
2
Athens
 
JW
Haab
 
OP
Raab
 
SO
et al. 
Leukokinetic studies: IV. the total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects.
J Clin Invest
1961
, vol. 
40
 (pg. 
989
-
995
)
3
Dancey
 
JT
Deubelbeiss
 
KA
Harker
 
LA
Finch
 
CA
Neutrophil kinetics in man.
J Clin Invest
1976
, vol. 
58
 
3
(pg. 
705
-
715
)
4
McMillan
 
R
Scott
 
JL
Leukocyte labeling with 51-Chromium: I. technic and results in normal subjects.
Blood
1968
, vol. 
32
 
5
(pg. 
738
-
754
)
5
Peters
 
AM
Roddie
 
ME
Danpure
 
HJ
et al. 
99Tcm-HMPAO labelled leucocytes: comparison with 111In-tropolonate labelled granulocytes.
Nucl Med Commun
1988
, vol. 
9
 
6
(pg. 
449
-
463
)
6
Rankin
 
SM
The bone marrow: a site of neutrophil clearance.
J Leukoc Biol
2010
, vol. 
88
 
2
(pg. 
241
-
251
)
7
Vrieskoop
 
N
den Braber
 
I
de Boer
 
AB
et al. 
Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool.
Proc Natl Acad Sci U S A
2008
, vol. 
105
 
16
(pg. 
6115
-
6120
)
8
Atkins
 
PW
Physical Chemistry
1994
5th Ed
Oxford, UK
Oxford University Press
9
Bock
 
G
Schumann
 
WC
Basu
 
R
et al. 
Evidence that processes other than gluconeogenesis may influence the ratio of deuterium on the fifth and third carbons of glucose: implications for the use of 2H2O to measure gluconeogenesis in humans.
Diabetes
2008
, vol. 
57
 
1
(pg. 
50
-
55
)
10
Cronkite
 
EP
Kinetics of granulocytopoiesis.
Clin Haematol
1979
, vol. 
8
 
2
(pg. 
351
-
370
)
Sign in via your Institution